Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-04-07 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, as mandated by French commercial code and AMF regulations. This type of filing, which reports on share structure and voting rights, is most closely aligned with the general category of regulatory announcements or specific filings related to share capital changes. Given the options, it is a specific regulatory disclosure about share structure, but none of the codes perfectly match a 'Monthly Voting Rights Report'. However, it is a formal regulatory filing that reports on share structure changes/counts. It is not an AGM, 10-K, ER, or IR. It is a specific regulatory disclosure. Since it details the number of shares and voting rights, it relates to capital structure, but it is not a general financing announcement (CAP) or a transaction in own shares (POS). It is a mandatory periodic disclosure. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, mandatory regulatory disclosures that don't fit the primary categories, although it is very close to a share/capital update. Upon re-evaluation, this document reports the total number of shares and voting rights, which is a fundamental aspect of share capital structure. However, it is a periodic disclosure of existing shares, not an issuance or repurchase announcement. Since it is a mandatory regulatory filing detailing share counts, and 'RNS' is the general regulatory filing bucket, I will use RNS as the best fit for this specific, non-standardized regulatory report type, as it is not a major shareholding notification (MRQ) or a transaction (POS). The document is short and is a direct regulatory report, not an announcement of a report.
2021-04-07 French
bioMérieux announces the CE marking of 3 dengue immunoassays on VIDAS®
Regulatory Filings Classification · 95% confidence The document is a press release dated April 7, 2021, announcing that bioMérieux received CE marking for three new dengue immunoassays on the VIDAS® platform. This is a product/regulatory achievement announcement, not a periodic financial report (like 10-K or IR), an earnings call transcript (CT), or a formal shareholder communication (like DEF 14A or AGM-R). Since it announces a specific regulatory approval (CE marking) related to diagnostics, it falls under general regulatory or corporate news. Given the options, it is best classified as a general Regulatory Filing (RNS) as it pertains to a regulatory milestone, or potentially a Capital/Financing Update (CAP) if the product launch is considered a major strategic event, but RNS is the most appropriate fallback for specific regulatory news that isn't a standard financial filing.
2021-04-07 English
bioMérieux annonce le marquage CE de 3 immunoessais sur VIDAS® permettant de diagnostiquer la dengue
Regulatory Filings Classification · 91% confidence The document is a press release from bioMérieux dated April 7, 2021, announcing the CE marking (European conformity) of three new dengue diagnostic tests for their VIDAS® platform. This type of announcement, detailing a specific product development, regulatory milestone (CE mark), and its implications, is characteristic of a general corporate news release or an announcement related to product/business updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a news announcement about a business development (product approval/launch) and does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for a significant, non-financial, non-meeting-related corporate announcement is often the Regulatory Filings fallback (RNS), or potentially an Investor Presentation (IP) if it were structured as a deck, but here it reads like a press release. Given the options, and that it is a formal announcement of a business/product event, RNS (Regulatory Filings/General Announcement) is the best fit as a catch-all for significant, non-standard corporate news, although it is very close to an ER if it were financial results. Since it is purely product/regulatory news, RNS is selected as the most fitting general announcement category.
2021-04-07 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from bioMérieux dated March 24, 2021, announcing the CE marking of a new diagnostic test (VIDAS® TB IGRA) for latent tuberculosis infection. It details the product's features, clinical performance, and strategic importance. This type of announcement, which communicates significant business or product news to the public and investors, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it contained financial results. Since it is a product/regulatory milestone announcement rather than a formal financial report (like 10-K, IR, or ER highlights), and it doesn't fit other specific categories (like M&A, Dividend, or Management Change), the most appropriate general category is Regulatory Filings (RNS). It is not an announcement of a report publication (RPA) because it *is* the primary content, not just a notice that a report is attached.
2021-03-23 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release from bioMérieux announcing the CE marking of their new VIDAS® TB IGRA test on World Tuberculosis Day. It details the product's features, clinical performance, and strategic importance. This type of announcement, which communicates a significant business or product development event to the public and investors, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck. However, given the format is a news release announcing a product milestone and regulatory clearance (CE marking), and it does not fit the specific definitions for Earnings Release (ER), Capital Update (CAP), or Management Discussion (MDA), the most appropriate general category for a non-standard, important corporate announcement is Regulatory Filings (RNS). It is not a formal statutory report like a 10-K or IR, nor is it a transcript or a factsheet. The length (7312 chars) is substantial enough that it is not merely a brief announcement of a report (RPA).
2021-03-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2021, announcing that bioMérieux's subsidiary received a De Novo authorization from the US FDA for a respiratory panel including SARS-CoV-2. This type of announcement, detailing a specific regulatory approval or significant operational/product update, is characteristic of a general corporate announcement rather than a formal periodic financial report (like 10-K or IR) or a transcript. Since it is a specific, non-financial regulatory/product update announcement, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal communication to the market about a regulatory event, although it could also be considered a type of Investor Relations material. Given the options, RNS serves as the best fit for a specific regulatory milestone announcement that isn't a standard financial report or a management change.
2021-03-18 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.